Head-To-Head Survey: Cynosure (CYNO) & Koninklijke Philips (PHG)
Cynosure (NASDAQ: CYNO) and Koninklijke Philips (NYSE:PHG) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability.
Institutional and Insider Ownership
6.4% of Koninklijke Philips shares are owned by institutional investors. 2.9% of Cynosure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares Cynosure and Koninklijke Philips’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Koninklijke Philips||$20.08 billion||1.79||$1.87 billion||$2.03||18.86|
Koninklijke Philips has higher revenue and earnings than Cynosure. Cynosure is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks.
Koninklijke Philips pays an annual dividend of $0.73 per share and has a dividend yield of 1.9%. Cynosure does not pay a dividend. Koninklijke Philips pays out 36.0% of its earnings in the form of a dividend.
This is a summary of current ratings and recommmendations for Cynosure and Koninklijke Philips, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cynosure presently has a consensus target price of $63.00, indicating a potential upside of Infinity. Koninklijke Philips has a consensus target price of $37.00, indicating a potential downside of 3.34%. Given Cynosure’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Cynosure is more favorable than Koninklijke Philips.
This table compares Cynosure and Koninklijke Philips’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Koninklijke Philips beats Cynosure on 8 of the 13 factors compared between the two stocks.
Cynosure Company Profile
Cynosure, Inc. develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women’s health. The Company also markets radiofrequency (RF), energy-sourced medical devices for surgical applications, such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. The Company sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names. Its product portfolio includes single energy source systems, as well as workstations that incorporate two or more different types of lasers or light-based technologies.
Koninklijke Philips Company Profile
Koninklijke Philips N.V. is the Netherlands-based health technology company. The Company’s segments include Personal Health businesses, Diagnosis & Treatment businesses, Connected Care & Health Informatics businesses, HealthTech Other and Legacy Items. The Personal Health businesses segment is engaged in the health continuum, delivering integrated, connected solutions that support healthier lifestyles and those living with chronic disease. The Diagnosis & Treatment businesses segment delivers precision medicine and treatment, and therapy. The Connected Care & Health Informatics businesses segment provides consumers, care givers and clinicians with digital solutions that facilitate care by enabling precision medicine and population health management. The HealthTech Other segment comprises such items, as innovation, emerging businesses, royalties, among others. The Legacy Items segment consists mainly of separation costs, legacy legal items, legacy pension costs, among others.
Receive News & Ratings for Cynosure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure and related companies with MarketBeat.com's FREE daily email newsletter.